<DOC>
	<DOCNO>NCT02404168</DOCNO>
	<brief_summary>The prior BEEP study involve patient switch brand generic structure manner . Other secondary comparison also make ( i.e . difference adverse effect seizure control ) . Some subject disparate , term generic similar brand . In follow study , BEEP subject show disparate result test assess reproducibility disparate result .</brief_summary>
	<brief_title>BEEP Follow Up : Evaluation Repeatability Lamotrigine Pharmacokinetics Epileptic Patients</brief_title>
	<detailed_description>This double-blind , multiple-dose , full replicate design , pharmacokinetic study lamotrigine `` enriched '' patient epilepsy previously participate HP-00048923 . LAMICTAL 100mg tablet commonly use generic lamotrigine 100mg tablet ( Teva ) compare pharmacokinetically .</detailed_description>
	<mesh_term>Lamotrigine</mesh_term>
	<mesh_term>Anticonvulsants</mesh_term>
	<criteria>Subject able provide inform consent enrol previous BEEP study . Subject male female 18 76 year age inclusive . Subject diagnosis epilepsy simple partial seizure and/or complex partial seizure , without secondary generalization primary generalize seizure Subject maintain stable dose regimen antiepileptic drug ( AEDs ) , include lamotrigine 200mg , 400mg , 600mg total daily dosage divide BID least 8 week prior Visit 1 screen period Subject willing switch brand generic lamotrigine Subject acceptable candidate venipuncture Subject willing stop OTC medication 24 hour prior 12 hour study visit Subject currently participate participate within last 2 month trial investigational drug experimental device Subject history status epilepticus within 12 month period prior Visit 1 . Subject medical condition , opinion investigator , could jeopardize subject 's health would compromise subject 's ability participate trial Subject psychiatric condition , opinion investigator , could jeopardize subject 's health would compromise subject 's ability participate trial confound interpretation trial data Subject know hypersensitivity lamotrigine Subject medical condition impact drug absorption ( e.g . gastric bypass surgery ) , include routine use ( i.e . daily weekly ) use acid blocker , antacid , antidiarrhea , stimulant , appetite suppressant , anti nausea medication drug modulate GI function Subject history alcohol drug abuse within previous two year Subject acute subacutely progressive CNS disease Subject moderate severe liver impairment assess alanine aminotransferase ( ALT ) , aspartate aminotransferase ( AST ) , total bilirubin level â‰¥5 time upper limit normal ( ULN ) . Subject moderate severe renal impairment assess creatinine clearance lower 50mL/min , use CockcroftGault formula Female subject childbearing potential eligible participate unwilling unable use medically acceptable method contraception throughout entire study period one week study complete . Medically acceptable method contraception may use subject and/or partner : condom spermicide , diaphragm spermicide , IUD without progesterone , vaginal spermicidal suppository , surgical sterilization partner ( ) abstinence Female subject pregnant nursing Female subject use hormonal contraceptive precaution include progesteronecoated IUD Subjects use hormonal replacement therapy Subject unwilling unable maintain approximate daily smoking use study Subject use rifampin nonAED strongly modulate lamotrigine level addition lamotrigine and/or vagus nerve stimulation and/or intermittent benzodiazepine use ( e.g . lorazepam , diazepam , clonazepam ) , subject take two concomitant AEDs Subject willing able adherent study protocol ( e.g . dose lamotrigine interact comedication ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>76 Years</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>